PCLM-2023: PEPFAR Community Led Monitoring (CLM)-Zambia
Closed
This grant is closed. A newer notice from the same program is open now: Advancing Global Health (DFOP0017890). Status: Closes February 14, 2027 (99 days left). It is in our archive of U.S. Mission to Zambia notices from 2022.
U.S. Mission to Zambia offered grants of up to $120,000 to the applicants described in the notice. It expected to make about 10 awards worth $1.2 million in total. Applications closed on September 6, 2022.
From the official notice on Grants.gov, last changed August 30, 2022. Checked November 7, 2026.
- Award ceiling$120,000
- Total funding$1.2 million
- Expected awards10
- Cost sharingNot required
- Funding typeGrant
Key dates
| Posted | July 1, 2022 |
|---|---|
| Deadline | September 6, 2022 |
| Archived by Grants.gov | September 28, 2022 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Not-for-profit organizations, including civil society, non-governmental organizations, and public and private educational institutions.
Is this a realistic fit?
- Past The U.S. President's Emergency Plan for AIDS Relief Programs awards averaged $146,897; this notice allows up to $120,000 per award.
- Most of the program's money (74% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
See attached NOFO for full funding opportunity.
Who has won The U.S. President's Emergency Plan for AIDS Relief Programs grants before
From fiscal 2021 to 2025, The U.S. President's Emergency Plan for AIDS Relief Programs (19.029) awarded $117 million across 794 grant awards, an average of $146,897 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Maryland | 1 | $89.9 million |
| Miscellaneous Foreign Awardees | 321 | $7.9 million | |
| Ho Chi Minh City HIV/AIDS Association | 4 | $673,404 | |
| Tamra for Social Development Organization (TDS) | 3 | $638,998 | |
| National Empowerment Network of People Living with HIV / AIDS (Nephak) | 3 | $513,403 |
Applying now
This notice no longer takes applications. Apply under the newer notice, DFOP0017890, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PCLM-2023 still open?
No. It closed on September 6, 2022. A newer notice is open: DFOP0017890, closes February 14, 2027 (99 days left).
Who can apply for PEPFAR Community Led Monitoring (CLM)-Zambia?
U.S. Mission to Zambia accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for PEPFAR Community Led Monitoring (CLM)-Zambia?
Closed September 6, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $120,000 each. About $1.2 million in total across about 10 awards.
Who has won The U.S. President's Emergency Plan for AIDS Relief Programs grants before?
The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Miscellaneous Foreign Awardees, Ho Chi Minh City HIV/AIDS Association. The program made 794 awards worth $117 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)